NEW YORK, July 14, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Sinovac Biotech Ltd. (NASDAQ:SVA) from April 30, 2013 through May 16, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Sinovac investors under the federal securities laws.
To join the Sinovac class action, go to http://www.rosenlegal.com/cases-1015.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Weidong Yin, Sinovac’s Chairman and CEO, bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; (2) such conduct would subject Sinovac to heightened regulatory scrutiny; and (3) as a result, Sinovac’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 1, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1015.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Apple Turns 50: From Garage Startup to AI Crossroads
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



